MedTrace Logo

Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered

NCT05518838 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2024-11-08

No results posted yet for this study

Summary

To provide OKN-007 for compassionate use in patients with diffuse midline glioma, H3 K27-altered (DMG), including diffuse intrinsic pontine glioma (DIPG), pediatric and young adult patients with high-grade diffuse midline glioma will be treated under this Intermediate-sized expanded access treatment protocol.

Conditions

  • Diffuse Midline Glioma, H3 K27M-Mutant
  • Diffuse Intrinsic Pontine Glioma

Interventions

DRUG

OKN-007

OKN-007 is an intravenously administrated drug being developed as a novel anti-cancer therapy against gliomas.

Sponsors & Collaborators

  • Oblato, Inc.

    lead INDUSTRY

Eligibility

Min Age
13 Months
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05518838 on ClinicalTrials.gov